Medpace MEDP 深 沪
已收盘 01-30 16:00:00 美东时间
582.48
-10.590
-1.79%
华盛通- 最 高595.91
- 今 开586.35
- 成交量 22.45万股
- 最 低 578.84
- 昨 收 593.07
- 总市值 164.07亿
- 52周最高 628.9155
- 市盈率 静 46.12
- 换手率 0.00%
- 52周最低 250.05
- 委 比 -85.71%
- 总股本 2816.82万
- 历史最高 628.9155
- 量 比 1.11
- 振 幅 2.88%
- 历史最低 21.76
- 每 手 1
- 风险率 118.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $525
Barclays analyst Luke Sergott maintains Medpace Hldgs (NASDAQ:MEDP) with a Underweight and raises the price target from $485 to $525.
2025-12-16 05:03
6 Healthcare Stocks With Strong Upward Momentum
Out with the old (tech), in with the new (healthcare). After several volatile w...
2025-11-19 01:59
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
BMO Capital Initiates Coverage On Medpace Hldgs with Market Perform Rating, Announces Price Target of $600
BMO Capital analyst Sean Dodge initiates coverage on Medpace Hldgs (NASDAQ:MEDP) with a Market Perform rating and announces Price Target of $600.
2025-11-13 17:32
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
2025-10-27 09:45
Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings
Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter e...
2025-10-24 21:55
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655
Mizuho analyst Ann Hynes maintains Medpace Hldgs (NASDAQ:MEDP) with a Outperform and raises the price target from $575 to $655.
2025-10-24 21:26
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.
2025-10-24 00:00
